Invion Ltd (IVX) - Total Assets

Latest as of June 2025: AU$9.49 Million AUD ≈ $6.71 Million USD

Based on the latest financial reports, Invion Ltd (IVX) holds total assets worth AU$9.49 Million AUD (≈ $6.71 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Invion Ltd - Total Assets Trend (2001–2025)

This chart illustrates how Invion Ltd's total assets have evolved over time, based on quarterly financial data. Also see how much is Invion Ltd worth for the company's overall valuation and market capitalisation.

Invion Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

Invion Ltd's total assets of AU$9.49 Million consist of 9.8% current assets and 90.2% non-current assets. Review IVX current and long-term liabilities to assess the company's total debt and financial obligations.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 9.0%
Accounts Receivable AU$0.00 0.0%
Inventory AU$0.00 0.0%
Property, Plant & Equipment AU$0.00 0.0%
Intangible Assets AU$8.54 Million 90.0%
Goodwill AU$0.00 0.0%

Asset Composition Trend (2001–2025)

This chart illustrates how Invion Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Invion Ltd for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Invion Ltd's current assets represent 9.8% of total assets in 2025, an increase from 0.0% in 2001.
  • Cash Position: Cash and equivalents constituted 9.0% of total assets in 2025, up from 0.0% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 89.0% of total assets, an increase from 77.0% in 2001.
  • Asset Diversification: The largest asset category is intangible assets at 90.0% of total assets.

Invion Ltd Competitors by Total Assets

Key competitors of Invion Ltd based on total assets are shown below.

Company Country Total Assets
Galderma Group N
SW:GALD
Switzerland CHF12.88 Billion
IPSEN SA SP.ADR 1/4/ EO 1
F:I7G0
Germany €6.94 Billion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥19.57 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥13.81 Billion
Harbin Gloria Pharmaceuticals
SHE:002437
China CN¥3.14 Billion
Teyi Pharmaceutical Group Co Ltd
SHE:002728
China CN¥2.33 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion

Invion Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.75 2.05 2.81
Quick Ratio 0.75 3.25 2.81
Cash Ratio 0.69 0.77 0.00
Working Capital AU$-304.96K AU$1.07 Million AU$590.04K

Invion Ltd - Advanced Valuation Insights

This section examines the relationship between Invion Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.88
Latest Market Cap to Assets Ratio 0.25
Asset Growth Rate (YoY) -38.6%
Total Assets AU$9.49 Million
Market Capitalization $2.36 Million USD

Valuation Analysis

Below Book Valuation: The market values Invion Ltd's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Invion Ltd's assets decreased by 38.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Invion Ltd (2001–2025)

The table below shows the annual total assets of Invion Ltd from 2001 to 2025.

Year Total Assets Change
2025-06-30 AU$9.49 Million
≈ $6.71 Million
-38.59%
2024-06-30 AU$15.45 Million
≈ $10.93 Million
-18.88%
2023-06-30 AU$19.05 Million
≈ $13.48 Million
-4.96%
2022-06-30 AU$20.04 Million
≈ $14.18 Million
+255.20%
2021-06-30 AU$5.64 Million
≈ $3.99 Million
-2.06%
2020-06-30 AU$5.76 Million
≈ $4.08 Million
-4.97%
2019-06-30 AU$6.06 Million
≈ $4.29 Million
-41.42%
2018-06-30 AU$10.35 Million
≈ $7.32 Million
+78.06%
2017-06-30 AU$5.81 Million
≈ $4.11 Million
-51.49%
2016-06-30 AU$11.98 Million
≈ $8.48 Million
-25.57%
2015-06-30 AU$16.10 Million
≈ $11.39 Million
+9.29%
2014-06-30 AU$14.73 Million
≈ $10.42 Million
-9.35%
2013-06-30 AU$16.25 Million
≈ $11.50 Million
+137.96%
2012-06-30 AU$6.83 Million
≈ $4.83 Million
+44.38%
2011-06-30 AU$4.73 Million
≈ $3.35 Million
+5.39%
2010-06-30 AU$4.49 Million
≈ $3.18 Million
-81.55%
2009-06-30 AU$24.32 Million
≈ $17.21 Million
+650.97%
2008-06-30 AU$3.24 Million
≈ $2.29 Million
-13.32%
2007-06-30 AU$3.74 Million
≈ $2.64 Million
-73.22%
2006-06-30 AU$13.95 Million
≈ $9.87 Million
+2.24%
2005-06-30 AU$13.64 Million
≈ $9.65 Million
+439.85%
2004-06-30 AU$2.53 Million
≈ $1.79 Million
+22.43%
2003-06-30 AU$2.06 Million
≈ $1.46 Million
+39.18%
2002-06-30 AU$1.48 Million
≈ $1.05 Million
+2.77%
2001-06-30 AU$1.44 Million
≈ $1.02 Million
--

About Invion Ltd

AU:IVX Australia Drug Manufacturers - Specialty & Generic
Market Cap
$2.36 Million
AU$3.34 Million AUD
Market Cap Rank
#29894 Global
#1733 in Australia
Share Price
AU$0.04
Change (1 day)
-13.33%
52-Week Range
AU$0.03 - AU$0.11
All Time High
AU$4.80
About

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more